

The role of endoscopic third ventriculostomy in the treatment of hydrocephalus

Artur Xhumari^{1,2}, Ermira Pajaj², Maren Ruka², Mithat Demneri², Mentor Petrela^{1,2}

¹Faculty of Medicine, University of Medicine, Tirana, Albania;

²Service of Neurosurgery, University Hospital Centre “Mother Theresa”, Tirana, Albania.

Corresponding author: Artur Xhumari, PhD;
Address: Dibra Street, 371, Tirana, Albania;
Telephone: +335692041867; E-mail: artur.xhumari@gmail.com

Abstract

Hydrocephalus (HCP) is the pathological accumulation of cerebro-spinal fluid (CSF). The conventional treatment has been extra cranial CSF shunting to another body cavity, peritoneum, cardiac atrium or pleura. Endoscopic third ventriculostomy (ETV) is an alternative for treatment of hydrocephalus that can eliminate the need for implantation of a lifelong ventricular shunt system. ETV is superior to shunt considering the economic costs of the procedure.

The aim of this study is to present the experience in the treatment of hydrocephalus by using ETV at the Neurosurgical Service of “Mother Theresa” Hospital in Tirana from the year 2008 to 2014. We report an overall mid-term success rate of 90% and support ETV as the first choice treatment of non-communicating hydrocephalus, or in shunt failure.

Keywords: hydrocephalus, neurosurgery, ventriculostomy.

Introduction

Hydrocephalus (HCP) is the pathological accumulation of cerebro-spinal fluid (CSF). Usually, symptomatic hydrocephalus is caused by an obstruction in CSF circulation. When the obstruction is localized outside the ventricles the condition is called communicating hydrocephalus. When the obstruction occurs within the ventricular system, preventing the communication between ventricles and subarachnoid space, the condition is called non-communicating HCP (1).

Since the 1950s, the conventional treatment has been extra cranial CSF shunting to another body cavity, peritoneum, cardiac atrium or pleura. Despite the development of new shunt materials and techniques, the failure rate associated with a shunt within the 1st year has remained high ranging from 25.7% to 36.8% (1-4). Endoscopic third ventriculostomy (ETV) is an alternative for treatment of HCP that can eliminate the need for implantation of a lifelong ventricular shunt system. Due to the application of endoscopic technology to intraventricular surgery, we are now able to perform third ventriculostomies in a minimally invasive fashion.

Methods

This was a consecutive case-series retrospective study. The data were collected from the patients' database at the University Hospital Centre "Mother Teresa" in Tirana for the period 2008-2014. All reports of patients operated on with the diagnosis of HCP were evaluated by collecting the indications for surgery, primary diagnosis, history, previous ETV, previous DVP, history of meningitis, and modality of treatment (VP shunt or ETV). If a VP shunt was performed after ETV, this was

considered a "failed ETV procedure".

ETV procedure was performed in the same centre from the same surgeon (first author of this article). Briefly, our ETV technique is as follows: Under general anesthesia, the head in neutral position in a horseshoe headrest. Using a right frontal mediopupillary curved incision, a burr hole is performed just shy to the coronal suture. Dural opening, ventriculo-puncture using a 6mm trocar, than a 0 degree endoscope is introduced. Usually we do not use the holding device. After the identification of the Monroe foramen, the endoscope is advanced in the third ventricle; the mammillary bodies are identified, and with Fogarty catheter 4F a perforation in the third ventricle floor, in the midline, is performed.

Results

From January 2008 to December 2014, 40 patients have been treated in our clinic (Table 1). The age range was from 0.9 to 69 years (median: 32 years); 14 (35%) patients were less than 20 years old. The follow-up period was 5 to 74 months (mean value: 57 months). Principal causes of hydrocephalus included HCP due to failed DVP (12 cases), tumoral aqueductal stenosis (11 cases) and persistent HCP after Chiari I malformation decompression or tumour removal (seven cases) (Table 2). Of note, in two cases the cause of hydrocephalus was cerebral tuberculosis during treatment or after. Transient complications were encountered in 1 (2,5%) case (left oculomotor palsy). There were no mortality events in our series. The overall success rate was 90%. In 4 cases (10%), ETV procedure has failed and a DVP was performed after 3-12 months (Table 3).

Table 1. Patients' data

Case	Age	Etiology of HCP	Comments	Time of ETV failure (months)
1	5	Intraventricular haemorrhage	Operated 4 yrs after the haemorrhage	
2	11	Intracranial Germinoma	Multiple locations	
3	1	Shunt malfunction		
4	49	Cranial trauma	Remote	
5	18	Persistent HCP	After posterior fossa ependymoma removal	
6	1,25	Neuroepithelial cyst	Intraventricular, causing acueductal stenosis	
7	63	iNPH ⁽¹⁾		12
8	43	Shunt malfunction		
9	10	Persistent HCP	postChiari I decompression	
10	8	Shunt malfunction		
11	46	Persistent HCP	temporal cavernomatous malformation removal	
12	33	Persistent HCP	postChiari I decompression	
13	19	Acquired aqueductal stenosis	history for tuberculosis	
14	66	Shunt malfunction		
15	4	Shunt malfunction		
16	3	Shunt malfunction		
17	27	Shunt malfunction		
18	27	Persistent HCP	postChiari I decompression	
19	21	Ventriculo-thalamo-pedunculare pendymoma	CHT+RT ⁽²⁾ as definitive treatment	
20	36	Persistent HCP	postChiari I decompression	
21	67	Shunt malfunction	VP shunt for NPH, SDH ⁽³⁾ , shunt removal	3
22	64	Shunt malfunction		
23	55	Shunt malfunction		
24	64	NPH	after III ventricle CM ⁽⁴⁾ removal	
25	47	Shunt malfunction	Shunt for residual HCP after ventricular tumor removal	
26	36	Pineal region lesion		
27	45	Pineal region lesion		
28	67	Tentorial notch meningioma		
29	24	Pineal region lesion	NF1 ⁽⁵⁾ , Intratumoral haemorrhage at ETV failure	9

30	25	Congenital aqueductal stenosis	Macrocrania, recently signs of increased ICP ⁽⁶⁾	
31	45	Shunt malfunction		
32	0,9	Tubercular meningitis	2 months after beginning specific treatment	
33	5	Pineal region lesion		
34	50	Posterior corpus callosum GBM ⁽⁷⁾		
			Periaqueductal hyperintensity in T2 and FLAIR MRI ⁽⁸⁾ sequences, extending to the right thalamus	
35	2	Acquired aqueductal stenosis		
36	18	Pineal region lesion	NF1	
37	60	NPH	5 months before SAH ⁽⁹⁾	4
38	31	Persistent HCP	postChiari I decompression	
39	69	Pineal region metastasis		
40	65	LOVA ⁽¹⁰⁾		

(1) iNPH – idiopathic normal pressure hydrocephalus; (2) CHT + RT – chemotherapy and radiotherapy; (3) SDH – subdural hematoma; (4) CM – cavernous malformation; (5) NF1 – neurofibromatosis type 1; (6) ICP – intracranial pressure; (7) GBM – glioblastoma multiforme; (8) FLAIR MRI – Fluid-attenuated inversion recovery magnetic resonance imaging; (9) SAH – subarachnoidal haemorrhage; (10) LOVA - Long-standing overt ventriculomegaly in adults.

Table 2. Causes of hydrocephalus treated with ETV

Causes of hydrocephalus	Number
Shunt malfunction	12
Tumours	11
Persistent HCP	7
NPH	2
TBC	2
Congenital aqueductal stenosis	1
Cranial trauma	1
iNPH	1
Intraventricular haemorrhage	1
LOVA	1
Intraventricular neuroepithelial cyst	1

Table 3. Cases with ETV failure

Case	Age	Aetiology of hydrocephalus	Comments	Time of ETV Failure (months)
7	63	iNPH		12
37	60	NPH	5 months before SAH	4
29	24	Pineal region lesion	NF1, Intratumoral haemorrhage at ETV failure	9
21	67	Shunt malfunction	VP shunt for NPH, SDH, shunt removal	3

Discussion

ETV was first performed in our institution in the year 2000 (M.P.) using a standard definition camera system. The new high definition 3 CCD system was acquired in 2008. This event was chosen to begin our study, because this system is the state-of-art in neuroendoscopy material, and coupled with eight years of learning curve, probably reflects the best results achievable by our team.

ETV success depends on patient's characteristics including age, origin of hydrocephalus, and history of shunt therapy. An Endoscopic Third Ventriculostomy Success Score (ETVSS) model has been constructed to predict success of therapy in childhood hydrocephalus. Several papers have shown that ETVSS closely may predict the actual success of ETV, serving as a useful tool to predict success of ETV (5-8). Previous CNS infection, intraventricular hemorrhage and previous history for myelomeningocele repair are considered risk factors for ETV success.

In our series, we did not have all the data to calculate the ETVSS, because this score was described in the year 2010, after the beginning of our study. Also this score is validated for childhood HCP.

In our series, the failures were seen in 4 (10%) patients. Three of them had normal pressure hydrocephalus, two idiopathic and one after subarachnoidal haemorrhage. Even though there are reports claiming the benefit of ETV in NPH (9) the selection of patients is the most critical variable in ETV success. Probably our patient selection has to be stricter in this setting. The other failure was probably due to tumoral hemorrhage closing the stoma.

Our success rate (90%) compares favourably with reported success rates of 79% (10).

The complication rate of ETV is 2.5% in our series, lower than the reported overall complication rate of

usually between 5% and 15% (11,12). Permanent morbidity is reported lower than 3% (11,12); in our series it was 0. The reported mortality of ETV is lower than 1% (11,12); in our series it was 0. Reported complications may include: SAH, meningitis, confusion, oculomotor palsy, diabetes insipidus, cerebrospinal fluid leak, herniation syndrome, confusion, decrease of consciousness, and loss of thirst. The incidence of infective complications in ETV (0% in our series) versus shunting has been reported to be significantly lower 1-5% vs. 1-20%. Moreover, different from shunting procedures, infections in children with third ventriculostomy have a more benign course, being generally controlled by antibiotic treatment alone (13). Our results compare very favourably with that of the literature.

However, as a method it requires considerable experience, and several studies report a relation of experience not only with success rates but also with complication avoidance (10,11,13).

ETV should be considered even in hydrocephalus due to intracerebral hemorrhage. However, performing an ETV with a blurred field of vision and distorted ventricular anatomy is a challenge for any endoscopic neurosurgeon and should be reserved for experienced neuroendoscopists (14). Our case of intracerebral haemorrhage was operated several years after the event, thus, the field of vision was clear.

Conclusions

Our results support the ETV as an established method for the treatment of non-communicating hydrocephalus in carefully selected patients. Our rates of success and complications compare very favourably with the literature. ETV has good results in selected cases of non-communicating HCP and of HCP previously shunted. Failure is seen within one year after the procedure, mostly in NPH.

Conflicts of interest: None declared.

References

1. Vogel TW, Bahuleyan B, Robinson S, Cohen AR. The role of endoscopic third ventriculostomy in the treatment of hydrocephalus. *J Neurosurg Pediatr* 2013;12:54-61.
2. Berry JG, Hall MA, Sharma V, Goumnerova L, Slonim AD, Shah SS. A multi-institutional, 5-year analysis of initial and multiple ventricular shunt revisions in children. *Neurosurgery* 2008;62:445-53.
3. Caldarelli M, Di Rocco C, La Marca F. Shunt complications in the first postoperative year in children with meningo-myelocele. *Childs Nerv Syst* 1996;12:748-54.
4. Choudhury AR. Avoidable factors that contribute to the complications of ventriculoperitoneal shunt in childhood hydrocephalus. *Childs Nerv Syst* 1990;6:346-9.
5. Kulkarni AV, Drake JM, Kestle JR, Mallucci CL, Sgouros S, Constantini S. Predicting who will benefit from endoscopic third ventriculostomy compared with shunt insertion in childhood hydrocephalus using the ETV Success Score. *J Neurosurg Pediatr* 2010;6:310-5.
6. Jernigan SC, Berry JG, Graham DA, Goumnerova L. The comparative effectiveness of ventricular shunt placement versus endoscopic third ventriculostomy for initial treatment of hydrocephalus in infants. *J Neurosurg Pediatr* 2014;13:295-300.
7. Naftel RP, Reed GT, Kulkarni AV, Wellons JC. Evaluating the Children's Hospital of Alabama endoscopic third ventriculostomy experience using the Endoscopic Third Ventriculostomy Success Score: an external validation study. *J Neurosurg Pediatr* 2011;8:494-501.
8. Kulkarni AV, Riva-Cambrin J, Browd SR. Use of the ETV Success Score to explain the variation in reported endoscopic third ventriculostomy success rates among published case series of childhood hydrocephalus. *J Neurosurg Pediatr* 2011;7:143-6.
9. Paidakakos N, Borgarello S, Naddeo M. Indications for endoscopic third ventriculostomy in normal pressure hydrocephalus. *Acta Neurochir Suppl* 2012;113:123-7.
10. Dusick JR, McArthur DL, Bergsneider M. Success and complication rates of endoscopic third ventriculostomy for adult hydrocephalus: a series of 108 patients. *Surg Neurol* 2008;69:5-15.
11. Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy: a systematic review. *Acta Neurochir Suppl* 2012;113:149-53.
12. Di Rocco C, Massimi L, Tamburrini G. Shunts vs endoscopic third ventriculostomy in infants: are there different types and/or rates of complications? A review. *Childs Nerv Syst* 2006;22:1573-89.
13. Schroeder HW, Niendorf WR, Gaab MR. Complications of endoscopic third ventriculostomy. *J Neurosurg* 2002;96:1032-40.
14. Oertel JM, Mondorf Y, Baldauf J, Schroeder HW, Gaab MR. Endoscopic third ventriculostomy for obstructive hydrocephalus due to intracranial hemorrhage with intraventricular extension. *J Neurosurg* 2009;111:1119-26.